Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 1Gastrointestinal Stromal Tumors 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 10Cisplatin 9Erlotinib Hydrochloride 8Carboplatin 7icotinib 5Gefitinib 5Docetaxel 5endostar protein 3Zoledronic Acid 3Radiotherapy 3Paclitaxel 3Gemcitabine 3Endostatins 3Afatinib 3tislelizumab 2pembrolizumab 2osimertinib 2lorlatinib 2flurbiprofen axetil 2dexamethasone 21-phosphate 2atezolizumab 2Vinorelbine 2Surgical Procedures, Operative 2Saline Solution 2Nivolumab 2Drug Therapy 2Dexamethasone 2Chemoradiotherapy 2trametinib 1spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Carcinoma, Non-Small-Cell Lung × Caffeine × Clear all
NCT01402089 2016-02-02

Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients

Cantonal Hospital of St. Gallen

Phase 4 Completed
54 enrolled
GastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡